Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.
NSCLC
SCLC
bispecific
lung cancer
nanobodies
targeted therapies
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Jun 2023
07 Jun 2023
Historique:
received:
17
02
2023
revised:
02
06
2023
accepted:
05
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.
Identifiants
pubmed: 37373003
pii: ijms24129855
doi: 10.3390/ijms24129855
pmc: PMC10298459
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Cancer Res. 2020 Jun 1;26(11):2615-2625
pubmed: 32034073
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Future Oncol. 2022 Feb;18(6):639-647
pubmed: 34911336
FEBS J. 2021 Apr;288(7):2084-2102
pubmed: 32780549
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Cancer Cell Int. 2022 Sep 7;22(1):279
pubmed: 36071488
Lancet Oncol. 2022 Jun;23(6):781-792
pubmed: 35576957
J Clin Oncol. 2023 Jun 1;41(16):2893-2903
pubmed: 36689692
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Lancet Oncol. 2022 Aug;23(8):1055-1065
pubmed: 35803286
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jul;13(4):e1697
pubmed: 33470555
N Engl J Med. 2021 Jun 24;384(25):2382-2393
pubmed: 34161704
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Front Oncol. 2021 Oct 01;11:713530
pubmed: 34660278
N Engl J Med. 2022 Jan 6;386(1):24-34
pubmed: 34986285
Anal Bioanal Chem. 2019 Mar;411(9):1703-1713
pubmed: 30734854
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Lancet. 2020 Jun 13;395(10240):1835-1844
pubmed: 32534646
J Clin Oncol. 2021 Oct 20;39(30):3391-3402
pubmed: 34339292
Biomark Res. 2021 May 26;9(1):38
pubmed: 34039409
Ann Oncol. 2020 Dec;31(12):1725-1733
pubmed: 33007380
Cancer Res Treat. 2019 Jul;51(3):951-962
pubmed: 30309221
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
Drug Discov Today. 2016 Jul;21(7):1076-113
pubmed: 27080147
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Clin Oncol. 2023 Feb 20;41(6):1213-1227
pubmed: 36327426
Nat Commun. 2022 Mar 18;13(1):1450
pubmed: 35304457
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Drugs. 2022 Aug;82(12):1333-1339
pubmed: 35986837
Clin Cancer Res. 2020 Jun 1;26(11):2654-2663
pubmed: 31911548
J Hematol Oncol. 2019 Jun 18;12(1):61
pubmed: 31215500
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Mol Cancer Ther. 2020 Oct;19(10):2044-2056
pubmed: 32747419
Front Immunol. 2017 Nov 02;8:1442
pubmed: 29163515
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494